Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioXcel Therapeutics (BTAI) Share-based Compensation (2022 - 2025)

BioXcel Therapeutics (BTAI) has 4 years of Share-based Compensation data on record, last reported at $581000.0 in Q3 2025.

  • For Q3 2025, Share-based Compensation fell 68.85% year-over-year to $581000.0; the TTM value through Sep 2025 reached $2.1 million, down 78.72%, while the annual FY2024 figure was $6.2 million, 66.93% down from the prior year.
  • Share-based Compensation reached $581000.0 in Q3 2025 per BTAI's latest filing, down from $1.6 million in the prior quarter.
  • Across five years, Share-based Compensation topped out at $6.1 million in Q2 2023 and bottomed at -$199000.0 in Q4 2024.
  • Average Share-based Compensation over 4 years is $3.0 million, with a median of $3.6 million recorded in 2023.
  • Peak YoY movement for Share-based Compensation: plummeted 105.53% in 2024, then surged 47.21% in 2025.
  • A 4-year view of Share-based Compensation shows it stood at $4.5 million in 2022, then dropped by 20.85% to $3.6 million in 2023, then crashed by 105.53% to -$199000.0 in 2024, then surged by 391.96% to $581000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Share-based Compensation were $581000.0 in Q3 2025, $1.6 million in Q2 2025, and $180000.0 in Q1 2025.